|Payment & Shipping Terms ||Supply Capacity |
|Payment Terms:||L/C, T/T, WU||Production Capacity:||1000 kg/Year|
|Min. Order:||25 Kilogram||Packing:||According to customer...|
|Means of Transport:||Ocean, Air, Land||Delivery Date:||Within 7 days|
Daunorubicin hydrochloride (CAS: 23541-50-6)
UN 2811 6.1/PG 3
Daunorubicin hydrochloride Usage And Synthesis
Dark Red Crystals
anti-neoplastic LD50 in mice 26 mg/kg
A DNA intercalator which may suppress acute leukemia proliferation
Anthracycline antibiotic related to the rhodomycins. Antineoplastic
Orange-red powder. Thin red needles decomposing at 188-190℃. An anti-cancer drug.
Air & Water Reactions
Daunorubicin hydrochloride may emit toxic oxides of nitrogen when heated.
Anticancer agent that is clinically used to treat nonlymphocytic leukaemia. Inhibits RNA and DNA synthesis and causes DNA fragmentation in vivo .
Daunorubicin or daunomycin is chemotherapeutic of the anthracycline family that is given as a treatment for some types of cancer. It is most commonly used to treat specific types of leukemia (acute myeloid leukemia and acute lymphocytic leukemia). It was initially isolated from Streptomyces peucetius.
A liposomal formulation of daunorubicin, liposomal daunorubicin.
It slows or stops the growth of cancer cells in the body. Treatment is usually performed together with other chemotherapy medicine (such as cytarabine), and its administration depends on the type of tumor and the degree of response.
In addition to its major use in treating AML, daunorubicin is also used to treat neuroblastoma. Daunorubicin has been used with other chemotherapy agents to treat the blastic phase of chronic myelogenous leukemia.
Daunorubicin is also used as the starting material for semi-synthetic manufacturing of doxorubicin, epirubicin and idarubicin.
Mechanism of action
Similar to Doxorubicin, Daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunomycin effectively binds to every 3 base pairs and induces a local unwinding angle of 8°, but negligible distortion of helical conformation. It can also induce histone eviction from chromatin upon intercalation.
Route of administration
Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death. Daunorubicin has been used intravitreally (inside the eye) for the purposes of preventing proliferative vitreoretinopathy, a common complication following retinal detachment surgery, but has not been found to be effective and is not used for any other ophthalmic purposes at this time.
Packing: 25KG drum
Category: Antineoplastic Drugs API
Related Category: Other Pharmaceutical API
Veterinary Medicine API
Diagnostic Agents API
Vitamin Preparation API
Psychotropic Drugs API